Abstract:Background We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene–related peptide receptor, for the prevention of episodic migraine. Methods We randomly assigned patients to receive a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo monthly for 6 months. The primary end point was the change from baseline to months 4 through 6 in the mean number of migraine days per month. Secondary end points were a 50% or greater reduction in mean migraine days per month, change in the number of days of use of acute migraine–specific medication, and change in scores on the physical-impairment and everyday-activities domains of the Migraine Physical Function Impact Diary (scale transformed to 0 to 100, with higher scores representing greater migraine burden on functioning). Results A total of 955 patients underwent randomization: 317 were assigned to the 70-mg erenumab group, 319 to the 140-mg erenumab group, and 319 to the placebo group. The mean number of migraine days per month at baseline was 8.3 in the overall population; by months 4 through 6, the number of days was reduced by 3.2 in the 70-mg erenumab group and by 3.7 in the 140-mg erenumab group, as compared with 1.8 days in the placebo group (P<0.001 for each dose vs. placebo). A 50% or greater reduction in the mean number of migraine days per month was achieved for 43.3% of patients in the 70-mg erenumab group and 50.0% of patients in the 140-mg erenumab group, as compared with 26.6% in the placebo group (P<0.001 for each dose vs. placebo), and the number of days of use of acute migraine–specific medication was reduced by 1.1 days in the 70-mg erenumab group and by 1.6 days in the 140-mg erenumab group, as compared with 0.2 days in the placebo group (P<0.001 for each dose vs. placebo). Physical-impairment scores improved by 4.2 and 4.8 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 2.4 points in the placebo group (P<0.001 for each dose vs. placebo), and everyday-activities scores improved by 5.5 and 5.9 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 3.3 points in the placebo group (P<0.001 for each dose vs. placebo). The rates of adverse events were similar between erenumab and placebo. Conclusions Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduced migraine frequency, the effects of migraines on daily activities, and the use of acute migraine–specific medication over a period of 6 months. The long-term safety and durability of the effect of erenumab require further study. (Funded by Amgen and Novartis; STRIVE ClinicalTrials.gov number, NCT02456740 .) Supported by Amgen and Novartis. Erenumab is codeveloped by Amgen and Novartis. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the STRIVE investigators and patients for their participation and commitment to this work, and Lori (Gorton) Smette, Ph.D. (an Amgen employee), and Devon Allen, B.Sc., of Fishawack Communications (funded by Amgen) for medical-writing support. Source Information From the National Institute for Health Research–Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London (P.J.G.); the Department of Neurology, Charité Universitätsmedizin Berlin, Berlin (U.R.); the Neuro Center, St. Göran Hospital, Stockholm (Y.H.); the Department of Neurology, Headache Outpatient Clinic, Medical University of Innsbruck, Innsbruck, Austria (G.B.); Mercy Research, St. Louis (J.H.B.); and the Departments of Global Biostatistical Science (F.Z.), Global Health Economics (S.S.), and Global Development (H.P., D.D.M., R.A.L.), Amgen, Thousand Oaks, CA. Address reprint requests to Dr. Goadsby at King’s College London, Wellcome Foundation Bldg., King’s College Hospital, London SE5 9PJ, United Kingdom, or at peter.goadsby@kcl.ac.uk . <div class="accessOptions" -Abstract Truncated-

Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results

Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months

Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study

Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study

Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON)

Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study

The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)

Retrospective Observational Study on 209 Patients

Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey

Erenumab versus topiramate: migraine-related disability, impact and health-related quality of life

Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers.

Two-year, real-world erenumab persistence and quality of life data in 82 pooled patients with abrupt onset, unremitting, treatment refractory headache and a migraine phenotype: New daily persistent headache or persistent post-traumatic headache in the majority of cases

CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension

Real-World Experience of Erenumab in Patients with Migraine in Germany: The SPECTRE Study

Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis

A Controlled Trial of Erenumab for Episodic Migraine

Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment

Impact of a reimbursement policy change on treatment with erenumab in migraine – a real-world experience from Germany

Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A—real-world data from a preliminary cohort study